BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 16, 2012
 |  BioCentury  |  Strategy

Karo Bio's next act

Pfizer deal unlocks value in Karo Bio's preclinical programs

Karo Bio AB thinks its deal with Pfizer Inc. will change the common perception that the company has nothing of value but eprotirome.

Eprotirome, a thyroid hormone receptor agonist, is in the Phase III AKKA trial in 630 patients with heterozygous familial hypercholesterolemia (HeFH). Interim three-month data from the first 150 patients are expected in 2Q12.

Last October, Karo Bio decided to spin out its preclinical operations into a subsidiary to separate them from eprotirome and to sharpen the company's focus, President and CEO Per Bengtsson told BioCentury. "It's difficult to pursue preclinical projects while doing such a large Phase III trial," he said.

He added that Karo Bio had enough money to finish the trial, but not enough to pursue the company's basket of preclinical projects in parallel.

The Pfizer deal will now help finance the preclinical programs as well as give them more visibility. In late December, the companies partnered to discover and develop small molecule RAR-related orphan receptor C (RORC; RORgamma) modulators to treat autoimmune diseases.

Karo Bio is eligible for up...

Read the full 877 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >